Author

Jurij Hanzel 1

1 University Medical Centre Ljubljana,Ljubljana,Slovenia

BIO-NAIVE CROHN'S DISEASE PATIENTS WITH LONG-STANDING DISEASE BENEFIT FROM USTEKINUMAB TREATMENT: REAL WORLD EXPERIENCE

Vedran Tomasic, David Drobne, Vladimir Borzan, Alen Bišćanin, Jurij Hanzel, Vlasta Orsic Fric, Petra Ćaćić, Borut Stabuc, Doris Ogresta, Dominik Kralj, Zdravko Dorosulic, Davor Hrabar

BIOPSIES FROM ULCER EDGE YIELD HIGHER HISTOLOGICAL ACTIVITY SCORES THAN BIOPSIES NEXT TO ULCER IN ACTIVE ULCERATIVE COLITIS

Gregor Novak, Nejc Sever, Jurij Hanzel, Matic Koželj, Tina Kurent, Natasa Smrekar, Borut Stabuc, David Drobne, Nina Zidar

INDUCTION AND EARLY MAINTENANCE VEDOLIZUMAB TROUGH LEVELS PREDICT MUCOSAL HEALING IN INFLAMMATORY BOWEL DISEASE

Jurij Hanzel, Nejc Sever, Griet Compernolle, Sophie Tops, Ivan Ferkolj, Borut Stabuc, Natasa Smrekar, Matic Koželj, Tina Kurent, Gregor Novak, Ann Gils, David Drobne

Peak ustekinumab concentration after intravenous loading dose predicts faecal calprotectin normalisation in Crohn's disease: potential role for therapeutic drug monitoring?

David Drobne, Jurij Zdovc, Tina Kurent, Jurij Hanzel, Nejc Sever, Katarina Javornik, Katja Tuta, Matic Koželj, Natasa Smrekar, Gregor Novak, Ivan Ferkolj, Borut Stabuc, Tomaz Vovk, Iztok Grabnar

SHORT TERM AZATHIOPRINE CO-TREATMENT DOES NOT IMPACT LONG TERM CLINICAL OUTCOME IN INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB, BUT HAS INFLIXIMAB-SPARING EFFECT

David Drobne, Tina Kurent, Sasa Golob, Polona Svegl, Polona Rajar, Jurij Hanzel, Matic Koželj, Gregor Novak, Natasa Smrekar, Ivan Ferkolj, Borut Stabuc

Survival in patients with missed upper gastrointestinal cancer during oesophagogastroduodenoscopy

Aleksandar Gavrić, Jurij Hanzel, Tina Zagar, Vesna Zadnik, Borut Stabuc

SWITCHING OUT OF CLASS IS THE MOST EFFECTIVE STRATEGY IN IBD PATIENTS WITH IMMUNOGENICITY AGAINST ANTI-TNF ANTIBODIES

Suzanne Irene Anjie, Jurij Hanzel, Krisztina Barbara Gecse, Geert R. D'Haens, Johannan Frank Brandse

Item 1 - 7 / 7
1